dc.contributor.author | Lazaridis, G. | en |
dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Lazaridis, G. | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Fountzilas, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:56Z | |
dc.date.available | 2018-06-22T09:53:56Z | |
dc.date.issued | 2008 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42105 | |
dc.description.abstract | Aim: Patients with liver metastases from cancer of unknown primary (CUPL) have a dismal prognosis. We retrospectively analysed their management and outcome and performed a systematic review of CUPL series published in the literature. Patients and methods: Electronic data from 49 CUPL patients referred to Hellenic Cooperative Oncology Group (HeCOG) centers were retrospectively studied for characteristics of clinical presentation, diagnostic workup, management, outcome and prognostic factors. A systematic literature review was undertaken in PubMed and EmBase databases. Results: All our patients (males: 31, females: 18; median age: 65) underwent a computed tomography scan (CT) of the abdomen, 71% a thoracic CT, 53% gastroscopy and 47% colonoscopy. The commonest histologic subtypes encountered were adenocarcinoma (N = 34) or undifferentiated carcinoma (N = 12). The liver was the only metastatic site in 38% of patients, while it was accompanied with other metastatic sites in 62% (the commonest: lung, bone and lymph nodes). Forty-seven patients received first-line chemotherapy (42 platinum based) and 16 second-line. An objective response was observed in six patients (12%), median survival being 10 months (95% CI, 7-13). In univariate analysis, good performance status and normal baseline serum CEA levels were correlated with superior survival, while in multivariate analysis only age < 55 (HR 0.16, p = 0.02) and the absence of extrahepatic disease (HR 0.21, p = 0.007) predicted for a better outcome. Published data from four relevant series (total patients = 662) parallel our findings. Conclusions: Patients with liver metastases from CUP are resistant to conventional types of treatment and carry a poor prognosis. Understanding the molecular biology of CUP is essential for the development of new, targeted effective therapies. © 2008 Elsevier Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Cancer treatment reviews | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Carboplatin | en |
dc.subject | Chemotherapy | en |
dc.subject | Computer assisted tomography | en |
dc.subject | Drug response | en |
dc.subject | Neoplasm staging | en |
dc.subject | Prognosis | en |
dc.subject | Retrospective studies | en |
dc.subject | Retrospective study | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Neutropenia | en |
dc.subject | Oxaliplatin | en |
dc.subject | Survival analysis | en |
dc.subject | Gastrointestinal toxicity | en |
dc.subject | Survival rate | en |
dc.subject | Review | en |
dc.subject | Docetaxel | en |
dc.subject | Overall survival | en |
dc.subject | Outcome assessment | en |
dc.subject | Survival | en |
dc.subject | Systematic review | en |
dc.subject | Bone metastasis | en |
dc.subject | Folinic acid | en |
dc.subject | Irinotecan | en |
dc.subject | Platinum complex | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Age distribution | en |
dc.subject | Logistic models | en |
dc.subject | Sex difference | en |
dc.subject | Clinical feature | en |
dc.subject | Analysis of variance | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Histopathology | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Blood toxicity | en |
dc.subject | Probability | en |
dc.subject | Risk assessment | en |
dc.subject | Survival time | en |
dc.subject | Literature | en |
dc.subject | Liver neoplasms | en |
dc.subject | Liver metastasis | en |
dc.subject | Lung metastasis | en |
dc.subject | Colonoscopy | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Unknown primary | en |
dc.subject | Carcinoembryonic antigen | en |
dc.subject | Protein blood level | en |
dc.subject | Cancer of unknown primary | en |
dc.subject | Multivariate analysis | en |
dc.subject | Capecitabine | en |
dc.subject | Cancer resistance | en |
dc.subject | Tomography | en |
dc.subject | Proportional hazards models | en |
dc.subject | Biopsy | en |
dc.subject | Abdominal scintiscanning | en |
dc.subject | Embase | en |
dc.subject | Gastroscopy | en |
dc.subject | Liver metastases | en |
dc.subject | Lymph nodes | en |
dc.subject | Medline | en |
dc.subject | Needle | en |
dc.subject | Thorax scintiscanning | en |
dc.subject | X-ray computed | en |
dc.title | Liver metastases from cancer of unknown primary (CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.ctrv.2008.05.005 | |
dc.description.volume | 34 | |
dc.description.issue | 8 | |
dc.description.startingpage | 693 | |
dc.description.endingpage | 700 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |